Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component.

Trial Profile

Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ATEM
  • Sponsors Takeda Pharmaceuticals International GmbH

Most Recent Events

  • 04 May 2012 Company added as trial association as reported by ClinicalTrials.gov.
  • 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 31 May 2011 Planned end date changed from 1 Mar 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top